Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 0.95 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.76 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.76 |
| ▸ | MTOR | P42345 | 1/20 | 0.63 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.62 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.62 |
| ▸ | PRKACA | P17612 | 1/20 | 0.62 |
| ▸ | PRKACG | P22612 | 1/20 | 0.62 |
| ▸ | PRKACB | P22694 | 1/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL960078 | 0.97 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL29439930 | 0.97 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL17255579 | 0.92 | PIK3CA (0.83) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL964649 | 0.92 | PIK3CA (0.86) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL960919 | 0.91 | PIK3CA (0.87) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL958760 | 0.90 | PIK3CA (0.86) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL959505 | 0.89 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL5303309 | 0.89 | PIK3CA (0.84) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL960842 | 0.88 | PIK3CA (0.82) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL960859 | 0.88 | PIK3CA (0.82) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812446-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-11-18 | — | — | EP | claimed |
| US-7872003-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-18 | — | — | US | claimed |
| US-20080207609-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | claimed |
| EP-1812446-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | claimed |
| WO-2006046040-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | claimed |
| EP-1812446-B1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LTD (GB) | 2015-11-18 | — | — | EP | disclosed |
| US-7872003-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-18 | — | — | US | disclosed |
| US-20080207609-A1 | Pharmaceutical compounds | PLRAMED LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1812446-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046040-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207609-A1 | Pharmaceutical compounds | PIK3CA, JAK2, PIK3R1 | PIK3CA 1/4885PIK3CB 14/4885PIK3CG 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.